We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
1-Year Est. Return
524.64%
This Fund
S&P 500
This Quarter
Est. Return
+12.11%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$177M
AUM Growth
-$47.3M
(-21%)
Cap. Flow
-$28.6M
Cap. Flow
% of AUM
-16.14%
Top 10 Holdings %
Top 10 Hldgs %
37.39%
Holding
117
New
21
Increased
27
Reduced
33
Closed
35
Avg Time Held Equity + Options
1.6
quarters
Top 10 Avg Time Held Equity + Options
0.8
quarters
Top 20 Avg Time Held Equity + Options
1.3
quarters
Avg Time Held Equity only
1.7
quarters
Top 10 Avg Time Held Equity only
0.8
quarters
Top 20 Avg Time Held Equity only
1.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$3.68M |
| 2 |
Fulcrum Therapeutics
FULC
|
+$3.52M |
| 3 |
Cerus
CERS
|
+$3.5M |
| 4 |
Arvinas
ARVN
|
+$3.29M |
| 5 |
NextCure
NXTC
|
+$3.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$12.8M |
| 2 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$5.49M |
| 3 |
MacroGenics
MGNX
|
+$4.75M |
| 4 |
Verastem
VSTM
|
+$4.27M |
| 5 |
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
|
+$3.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.54% |
| 2 | Financials | 5.83% |
| 3 | Miscellaneous | 2.47% |
| 4 | Industrials | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $8.6M | 4.86% |
61,897
+5,271
| +9% | +$658K |
2020 Q4
3 quarters
|
|
2
Veracyte
VCYT
$3.47B
| $8.34M | 4.72% |
179,548
+28,687
| +19% | +$1.25M |
2021 Q1
2 quarters
|
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.13M | 4.59% |
45,941
+8,188
| +22% | +$1.32M |
2020 Q4
3 quarters
|
|
4
DELISTED
Merus
MRUS
| $7.61M | 4.3% |
345,964
+25,149
| +8% | +$539K |
2021 Q1
2 quarters
|
|
|
AMYT
5
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $6.22M | 3.52% |
516,221
+59,684
| +13% | +$674K |
2020 Q4
3 quarters
|
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.75M | 3.25% |
52,469
+2,434
| +5% | +$253K |
2020 Q4
3 quarters
|
|
|
7
Cogent Biosciences
COGT
$4.87B
| $5.7M | 3.22% |
677,900
+479,655
| +242% | +$3.68M |
2020 Q4
3 quarters
|
|
8
Immatics
IMTX
$1.04B
| $5.69M | 3.22% |
437,866
+148,458
| +51% | +$1.89M |
2021 Q1
2 quarters
|
|
|
9
Fulcrum Therapeutics
FULC
$281M
| $5.24M | 2.96% |
+185,691
| New | +$3.52M |
2021 Q3
0 quarters
|
|
|
10
NextCure
NXTC
$28.7M
| $4.86M | 2.75% |
60,109
+36,317
| +153% | +$3.18M |
2021 Q2
1 quarter
|
|
11
Insmed
INSM
$21.1B
| $4.81M | 2.72% |
174,588
-2,845
| -2% | -$74.6K |
2020 Q4
3 quarters
|
|
|
RACB
12
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $4.66M | 2.64% |
473,396
-22,459
| -5% | -$222K |
2021 Q1
2 quarters
|
|
13
United Therapeutics
UTHR
$23.3B
| $3.91M | 2.21% |
21,189
+5,900
| +39% | +$1.16M |
2020 Q4
3 quarters
|
|
14
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.8M | 2.15% |
101,890
-11,368
| -10% | -$395K |
2020 Q4
3 quarters
|
|
|
15
Cerus
CERS
$455M
| $3.77M | 2.13% |
619,369
+600,678
| +3,214% | +$3.5M |
2021 Q2
1 quarter
|
|
16
DELISTED
Immunogen Inc
IMGN
| $3.69M | 2.08% |
649,919
-177,668
| -21% | -$1.03M |
2020 Q4
3 quarters
|
|
|
SRRA
17
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $3.58M | 2.03% |
163,486
+24,181
| +17% | +$484K |
2020 Q4
3 quarters
|
|
18
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.27M | 1.85% |
57,704
-46,154
| -44% | -$2.79M |
2020 Q4
3 quarters
|
|
19
DELISTED
iTeos Therapeutics
ITOS
| $3.16M | 1.78% |
116,931
+41,420
| +55% | +$1.08M |
2021 Q2
1 quarter
|
|
20
Aclaris Therapeutics
ACRS
$511M
| $3.12M | 1.76% |
173,327
-15,392
| -8% | -$247K |
2021 Q1
2 quarters
|
|
|
21
Arvinas
ARVN
$447M
| $3.06M | 1.73% |
+37,249
| New | +$3.29M |
2021 Q3
0 quarters
|
|
22
Cypherpunk Technologies Inc
CYPH
$306M
| $2.49M | 1.41% |
+62,000
| New | +$1.17M |
2021 Q3
0 quarters
|
|
23
Halozyme
HALO
$12.4B
| $2.45M | 1.38% |
60,170
-6,503
| -10% | -$272K |
2020 Q4
3 quarters
|
|
24
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
| $2.38M | 1.35% |
139,200
+39,200
| +39% | +$611K |
2021 Q2
1 quarter
|
|
|
BLU
25
DELISTED
BELLUS Health Inc.
BLU
| $2.24M | 1.27% |
365,000
+155,067
| +74% | +$588K |
2021 Q2
1 quarter
|
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
BEAM
RAM
Silverarc Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Silverarc Capital Management held 117 positions worth $177M, down 21% from $224M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Silverarc Capital Management withdrew a net $28.6M in Q3 2021, closing 35 positions and reducing 33 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $12.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 85% a quarter earlier, followed by Financials and Miscellaneous.
Against the trend, Silverarc Capital Management opened a new position in Fulcrum Therapeutics worth $5.24M.
- Silverarc Capital Management's largest Q3 2021 buy was Fulcrum Therapeutics: 185,691 shares worth $5.24M.
- Silverarc Capital Management added most to Cogent Biosciences in Q3 2021, an estimated $3.68M increase.
- Silverarc Capital Management's biggest Q3 2021 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $5.49M.
- Silverarc Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2021, selling an estimated $12.8M.
- Silverarc Capital Management's ten largest holdings make up 37% of its $177M portfolio in Q3 2021.
- Silverarc Capital Management opened 21 new positions and closed 35 in Q3 2021.
- Silverarc Capital Management's portfolio value fell 21% quarter-over-quarter to $177M.
Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.